Abstract
Purpose:
To examine whether intraocular pressure (IOP) reduction by latanoprost correlates with the single nucleotide polymorphism (SNP) of the prostaglandin F2α (FP) receptor gene in glaucoma and ocular hypertension (OH) patients.
Methods:
We retrospectively examined clinical data of glaucoma and OH patients who were treated with latanoprost monotherapy in 1eye and who had at least two IOP measurements on different days at baseline and also when on the medication. In all patients, IOP reduction was evaluated by the percent IOP reduction (%ΔIOP), estimated by subtracting IOP fluctuations in the untreated fellow eye. Subjects were classified by %ΔIOP into 3 categories: 1) low responders (%ΔIOP <10%), 2) medium responders (%ΔIOP ≥10% and <25%), and 3) high responders (%ΔIOP ≥25%). Nine SNPs in FP receptor gene were examined. The correlation between the %ΔIOP and SNPs in the FP receptor gene was then analyzed.
Results:
A total of 82 patients (42 males, 40 females) met the eligibility criteria and were included. The average IOP of the treated eyes was decreased from 16.7 ± 3.2 mmHg (mean ± SD) to 14.2 ± 2.5 mmHg by latanoprost (mean %ΔIOP: 15.3 ± 10.5%). Three SNPs, rs1073611, rs1073610, and rs12093097 were in strong linkage disequilibrium. The %ΔIOP of the CC homozygote in rs12093097 (14.1 ± 1.3 % (mean ± SE)) was significantly lower than that of the T carrier (20.2 ± 2.1%, P = 0.039). The allele or genotype distributions of 3 SNPs, rs1073611, rs1073610, and rs12093097, were found to be significantly associated with the category of IOP response to latanoprost. The results of multivariate logistic regression analysis demonstrated that the genotype of rs12093097 was the only significant factor which has an effect on the IOP response to latanoprost (medium + high responders vs. low responders: P = 0.032; odds ratio, 0.103; 95% confidence interval, 0.013-0.824; predictive value, 67.1%).
Conclusions:
An association was found between rs12093097, rs1073611, and rs1073610 of the FP receptor gene and the response to latanoprost in patients with glaucoma and OH. These SNPs could affect the degree of IOP reduction by latanoprost.
Keywords: 503 drug toxicity/drug effects •
568 intraocular pressure